Phase 3 SELVA study evaluating QTORINâ„¢ rapamycin 3.9% anhydrous gel (QTORINâ„¢ rapamycin) for microcystic lymphatic ...
Phase 3 SELVA study evaluating QTORINâ„¢ rapamycin 3.9% anhydrous gel (QTORINâ„¢ rapamycin) for microcystic lymphatic ...
Phase 3 SELVA study evaluating QTORIN rapamycin 3.9% anhydrous gel (QTORIN rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated in Ma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback